Literature DB >> 23449888

ARF represses androgen receptor transactivation in prostate cancer.

Wenfu Lu1, Yingqiu Xie, Yufang Ma, Robert J Matusik, Zhenbang Chen.   

Abstract

Androgen receptor (AR) signaling is essential for prostate cancer (PCa) development in humans. The initiation of prostate malignancy and progression to a castration-resistant stage are largely contributed by the modulation of AR activity through its coregulatory proteins. We and others previously reported that p14 alternative reading frame (ARF) expression is positively correlated with the disease progression and severity of PCa. Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner. Endogenous ARF (p14ARF in human and p19ARF in mouse) and AR colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of p14ARF in PCa cells significantly attenuates the activities of androgen response region (ARR2)-probasin and prostate-specific antigen (PSA) promoters. The forced expression of p14ARF in cells resulted in a suppression of PSA and NK transcription factor locus 1 (NKX3.1) expression. Conversely, knockdown of endogenous p14ARF in human PCa cells with short hairpin RNA enhanced AR transactivation activities in a dose-dependent and p53-independent manner. Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR. Most importantly, we observed that the expression of PSA is reversely correlated with p14ARF in human prostate tissues. Taken together, our results reveal a novel function of ARF in modulation of AR transactivation in PCa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449888      PMCID: PMC3607697          DOI: 10.1210/me.2012-1294

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

Review 1.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

2.  The ARF tumor suppressor can promote the progression of some tumors.

Authors:  Olivier Humbey; Julia Pimkina; Jack T Zilfou; Michal Jarnik; Carmen Dominguez-Brauer; Darren J Burgess; Christine M Eischen; Maureen E Murphy
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

4.  Arf induces p53-dependent and -independent antiproliferative genes.

Authors:  Mei-Ling Kuo; Eric J Duncavage; Rose Mathew; Willem den Besten; Deqing Pei; Deanna Naeve; Tadashi Yamamoto; Cheng Cheng; Charles J Sherr; Martine F Roussel
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

5.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

6.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

7.  Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines.

Authors:  Marcus V Cronauer; Wolfgang A Schulz; Tatjana Burchardt; Rolf Ackermann; Martin Burchardt
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

8.  Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.

Authors:  Guoqing Liao; Liuh-Yow Chen; Aihua Zhang; Aparna Godavarthy; Fang Xia; Jagadish Chandra Ghosh; Hui Li; J Don Chen
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  The role of androgen receptor mutations in prostate cancer progression.

Authors:  G N Brooke; C L Bevan
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more
  16 in total

1.  Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

Authors:  Bo Li; Wenfu Lu; Zhenbang Chen
Journal:  Receptors Clin Investig       Date:  2014

2.  SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.

Authors:  W Lu; S Liu; B Li; Y Xie; M G Izban; B R Ballard; S A Sathyanarayana; S E Adunyah; R J Matusik; Z Chen
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

3.  Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Authors:  Styliani Karanika; Theodoros Karantanos; Likun Li; Jianxiang Wang; Sanghee Park; Guang Yang; Xuemei Zuo; Jian H Song; Sankar N Maity; Ganiraju C Manyam; Bradley Broom; Ana M Aparicio; Gary E Gallick; Patricia Troncoso; Paul G Corn; Nora Navone; Wei Zhang; Shuhua Li; Timothy C Thompson
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

4.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

5.  KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.

Authors:  Guoliang Li; Thanigaivelan Kanagasabai; Wenfu Lu; Mike R Zou; Shang-Min Zhang; Sherly I Celada; Michael G Izban; Qi Liu; Tao Lu; Billy R Ballard; Xinchun Zhou; Samuel E Adunyah; Robert J Matusik; Qin Yan; Zhenbang Chen
Journal:  Cancer Res       Date:  2020-08-31       Impact factor: 12.701

6.  Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.

Authors:  John T Minges; Gail Grossman; Ping Zhang; Tal Kafri; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2015-09-01       Impact factor: 5.157

7.  Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.

Authors:  Bo Li; Wenfu Lu; Qing Yang; Xiuping Yu; Robert J Matusik; Zhenbang Chen
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

8.  Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Authors:  Yingqiu Xie; Shenji Liu; Wenfu Lu; Qing Yang; Kieosha D Williams; Awadh A Binhazim; Brett S Carver; Robert J Matusik; Zhenbang Chen
Journal:  Mol Oncol       Date:  2014-05-21       Impact factor: 6.603

9.  SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.

Authors:  Wenfu Lu; Shenji Liu; Bo Li; Yingqiu Xie; Christine Adhiambo; Qing Yang; Billy R Ballard; Keiichi I Nakayama; Robert J Matusik; Zhenbang Chen
Journal:  Oncotarget       Date:  2015-01-20

10.  The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.

Authors:  Salma Siddiqui; Stephen J Libertini; Christopher A Lucas; Alan P Lombard; Han Bit Baek; Rachel M Nakagawa; Kristine S Nishida; Thomas M Steele; Frank U Melgoza; Alexander D Borowsky; Blythe P Durbin-Johnson; LiHong Qi; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2020-04-21       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.